$NANO.OL Breakout watch Nordic Nanovector 177Lu biotech
Diupdate
Nordic Nanovector NANO.OL pushing above NOK68 resistance on significant volume, closing at strong 70.3 before weekend. This indicates another attempt at breaking out of long time downtrend that has been effect since ATH back in december 2016.
Investors are seemingly very satisified with recent Q3 report and #ASH18 abstracts presented by CEO Eduardo Bravo and his team.
Nordic Nanovector Q3 2018 and ASH 2018 abstract presentation transcript
https://nanoinvestors.wordpress.com/2018/11/06/nordic-nanovector-q3-2018-and-ash-2018-abstract-presentation/
Novartis higlights 177Lu isotope for use in oncology radiopharmaceuticals
https://nanoinvestors.wordpress.com/2018/11/05/novartis-higlights-177lu-isotope-for-use-in-oncology-radiopharmaceuticals/
Betalutin FDA Fast Track Status
https://nanoinvestors.wordpress.com/betalutin-fda-fast-track-status/
Betalutin Receives Promising Innovative Medicine (PIM) Designation in the UK for the Treatment of Follicular Lymphoma.
https://nanoinvestors.wordpress.com/2018/10/25/betalutin-receives-promising-innovative-medicine-pim-designation-in-the-uk-for-the-treatment-of-follicular-lymphoma/
Nordic Nanovector Comprehensive Company Presentation Updated October 2018
https://nanoinvestors.wordpress.com/2018/10/15/nordic-nanovector-comprehensive-company-presentation-update-october-2018/
Nordic Nanovector mentioned by analyst ABG Sundal Collier as likely object of M&A interest
https://nanoinvestors.wordpress.com/2018/10/04/nordic-nanovector-mentioned-by-analyst-abg-sundal-collier-as-likely-object-of-ma-interest/
Nordic Nanovector Analyst Coverage
https://nanoinvestors.wordpress.com/nordic-nanovector-analyst-coverage/
Investors are seemingly very satisified with recent Q3 report and #ASH18 abstracts presented by CEO Eduardo Bravo and his team.
Nordic Nanovector Q3 2018 and ASH 2018 abstract presentation transcript
https://nanoinvestors.wordpress.com/2018/11/06/nordic-nanovector-q3-2018-and-ash-2018-abstract-presentation/
Novartis higlights 177Lu isotope for use in oncology radiopharmaceuticals
https://nanoinvestors.wordpress.com/2018/11/05/novartis-higlights-177lu-isotope-for-use-in-oncology-radiopharmaceuticals/
Betalutin FDA Fast Track Status
https://nanoinvestors.wordpress.com/betalutin-fda-fast-track-status/
Betalutin Receives Promising Innovative Medicine (PIM) Designation in the UK for the Treatment of Follicular Lymphoma.
https://nanoinvestors.wordpress.com/2018/10/25/betalutin-receives-promising-innovative-medicine-pim-designation-in-the-uk-for-the-treatment-of-follicular-lymphoma/
Nordic Nanovector Comprehensive Company Presentation Updated October 2018
https://nanoinvestors.wordpress.com/2018/10/15/nordic-nanovector-comprehensive-company-presentation-update-october-2018/
Nordic Nanovector mentioned by analyst ABG Sundal Collier as likely object of M&A interest
https://nanoinvestors.wordpress.com/2018/10/04/nordic-nanovector-mentioned-by-analyst-abg-sundal-collier-as-likely-object-of-ma-interest/
Nordic Nanovector Analyst Coverage
https://nanoinvestors.wordpress.com/nordic-nanovector-analyst-coverage/
Trade aktif
Tested support at 68 today.
Pernyataan Penyangkalan
Informasi dan publikasi tidak dimaksudkan untuk menjadi, dan bukan merupakan saran keuangan, investasi, perdagangan, atau rekomendasi lainnya yang diberikan atau didukung oleh TradingView. Baca selengkapnya di Persyaratan Penggunaan.